Reducing relapse in depressed outpatients with atypical features: a pilot study

Area of Science:

• Psychiatry
• Clinical Psychology
• Neuroscience

Background:

• Major depressive disorder (MDD) with atypical features presents with specific symptoms like hypersomnia and hyperphagia.
• These patients show a significant response to cognitive therapy (CT) or phenelzine (PHZ) compared to placebo.
• High rates of relapse and recurrence pose a significant challenge in managing atypical MDD.

Purpose of the Study:

• To investigate the efficacy of continuation phase treatment in preventing relapse and recurrence in patients with atypical MDD.
• To motivate further research into tolerable and effective long-term treatment strategies for this patient group.

Main Methods:

• Outpatients with DSM-III-R MDD and atypical features who responded to acute treatment were randomized.
• Participants were assigned to either continue or discontinue treatment for 8 months.
• A 16-month treatment-free follow-up period was implemented to assess long-term outcomes.

Main Results:

• Continuation of treatment resulted in significantly greater relapse and recurrence-free survival over 24 months post-acute phase.
• Kaplan-Meier estimates indicated substantially higher relapse rates (83%) in patients who discontinued treatment versus those who continued (49%).

Conclusions:

• Continuation treatment appears effective in reducing relapse and recurrence in patients with atypical MDD.
• Cognitive therapy (CT), in addition to pharmacotherapy, may serve as a valuable continuation phase treatment.
• Further large-scale studies are warranted to rigorously evaluate CT as a continuation strategy for atypical MDD.